Detailed price information for Pharming Group NV (PHGUF) from The Globe and Mail including charting and trades.

Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will ...

Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue incre ...

Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong ...

Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. References ...

Leiden, the Netherlands, April 23, 2025: Pharming Group N.V. ("Pharming” or "the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the National Institute for Health and Care Excellence ...

Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation ...

Pharming Group (NASDAQ:PHAR – Get Free Report) is projected to post its quarterly earnings results before the market opens on Thursday, March 13th. Analysts expect Pharming Group to post ...

Neither Pharming nor any of its affiliates and their respective directors, officers, employees or agents or any other person acting on their behalf in connection with the Offer shall be ...

Pharming Group N.V., a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases, announces that the board of directors ...

On Thursday, RBC Capital Markets updated its financial model for Pharming Group NV (PHARM:NA) stock, resulting in a higher price target for the biopharmaceutical company's shares.

Pharming has obtained acceptance undertakings from the three largest shareholders, accounting for 49.82% of Abliva's outstanding shares. The Offer is subject to customary regulatory approvals, and ...